Weight Loss: What Could Be Causing It?

Defining Clinically Significant Weight Loss

A loss of 5% or more of baseline body weight over 6 to 12 months, without intentional dieting or exercise changes, meets the clinical threshold for evaluation. That is the consensus definition used by the American Gastroenterological Association (AGA) and most internal medicine guidelines [1]. For a 180-pound person, that means roughly 9 pounds.

This distinction matters. Intentional weight loss through caloric restriction or GLP-1 receptor agonist therapy is a different clinical entity entirely. The concern with unintentional weight loss is that it often signals an underlying disease process that has not yet been diagnosed. A 2017 systematic review in the BMJ (N=25 studies, 8,278 patients) found that unintentional weight loss in patients over 65 carried a malignancy prevalence of 19.2%, with cancer diagnosed within 12 months of presentation in most cases [2].

The speed of weight loss also matters clinically. Rapid loss (greater than 10% in 6 months) correlates with higher odds of malignancy compared to slower, gradual decline [1]. Patients who lose weight gradually over a year are more likely to have a chronic inflammatory, psychiatric, or endocrine cause.

Not all self-reported weight loss is real. A prospective study published in the Archives of Internal Medicine found that 50% of patients reporting significant weight loss could not be confirmed by measured weights [3]. Objective documentation through serial weights in the medical record is the first step before pursuing an expensive workup.

Malignancy: The Diagnosis Clinicians Fear Most

Cancer accounts for 19% to 36% of all cases of clinically significant unintentional weight loss, making it the single most common category in adults over 50 [2]. The weight loss itself results from tumor-mediated cytokine release (particularly TNF-alpha and IL-6), increased basal metabolic rate, anorexia from tumor burden, and direct caloric loss through malabsorption in GI tract cancers.

The cancers most frequently associated with unexplained weight loss include lung, pancreatic, gastric, hepatobiliary, colorectal, and lymphoma [4]. Pancreatic cancer is particularly notorious. A retrospective cohort study at the Mayo Clinic (N=1,432 patients with new-onset unexplained weight loss) found that pancreatic and hepatobiliary cancers were the most commonly missed diagnoses on initial evaluation [5].

Dr. Nicola Barclay, lead author of a 2023 BMJ rapid review on cancer-associated weight loss, noted: "Unintentional weight loss of 5% or more should prompt cancer-directed investigation in any adult over 60, even in the absence of other alarm symptoms" [2]. The age-specific cancer risk is real. In patients under 40, malignancy accounts for fewer than 5% of cases; above 65, it exceeds 30%.

Age-appropriate cancer screening (colonoscopy, low-dose CT for lung cancer in eligible patients, mammography) should be current. If not, those screenings become part of the weight-loss workup rather than separate preventive care.

Gastrointestinal Disorders

GI diseases collectively represent the second most common cause, responsible for approximately 15% of unintentional weight loss diagnoses [1]. The mechanisms differ by condition: malabsorption in celiac disease and pancreatic insufficiency, inflammation-driven catabolism in Crohn's disease and ulcerative colitis, and motility-related early satiety in gastroparesis.

Celiac disease deserves special attention because it remains underdiagnosed. The condition affects approximately 1% of the global population, but a 2019 study in Gastroenterology estimated that 60% to 70% of celiac cases in the United States remain undiagnosed [6]. Tissue transglutaminase IgA (tTG-IgA) antibody testing is the recommended first-line screening test per American College of Gastroenterology guidelines [7].

Pancreatic exocrine insufficiency (PEI) is another frequently overlooked cause. It occurs not only in chronic pancreatitis but also after gastric bypass surgery, in long-standing diabetes, and in older adults. Fecal elastase-1 testing (values <200 mcg/g suggest insufficiency) is a simple, non-invasive screening tool [8].

Inflammatory bowel disease typically presents with additional symptoms (diarrhea, abdominal pain, bloody stools), but weight loss may precede GI symptoms by months, particularly in small-bowel Crohn's disease. C-reactive protein and fecal calprotectin levels can help screen for active inflammation before committing to endoscopy.

Peptic ulcer disease, chronic mesenteric ischemia, and small intestinal bacterial overgrowth (SIBO) round out the GI differential. Each has a distinct presentation, but all share the common feature of reducing effective caloric absorption or intake.

Endocrine and Metabolic Causes

Hyperthyroidism is the classic endocrine cause of weight loss despite a normal or increased appetite. Graves' disease accounts for 60% to 80% of hyperthyroidism cases in iodine-sufficient regions [9]. The diagnosis is straightforward: a suppressed TSH with elevated free T4 or free T3 confirms the diagnosis. Weight loss in hyperthyroidism results from increased metabolic rate, with resting energy expenditure rising by 15% to 20% in moderate thyrotoxicosis.

Uncontrolled type 1 or type 2 diabetes causes weight loss through glycosuria (urinary caloric loss) and impaired glucose utilization. A fasting glucose above 200 mg/dL or an HbA1c exceeding 10% should raise suspicion, particularly in a patient not previously known to have diabetes. The Endocrine Society's 2024 clinical practice guideline recommends checking HbA1c in all patients presenting with unexplained weight loss [10].

Adrenal insufficiency (both primary and secondary) is rare but dangerous when missed. Weight loss, fatigue, hypotension, and hyperpigmentation (in Addison's disease) form the classic presentation. An 8 AM cortisol level below 3 mcg/dL is diagnostic, while levels between 3 and 15 mcg/dL require ACTH stimulation testing for confirmation [10].

Pheochromocytoma, hyperparathyroidism, and carcinoid syndrome are uncommon but should remain on the differential when standard endocrine screening is unrevealing. A 24-hour urine metanephrines test or plasma free metanephrines test can screen for pheochromocytoma when clinical suspicion (episodic hypertension, diaphoresis, palpitations) exists.

Psychiatric and Behavioral Causes

Depression and anxiety disorders are responsible for 10% to 20% of unexplained weight loss cases across all age groups [1]. In older adults, depression-related weight loss is especially concerning because it compounds sarcopenia and increases fall risk, creating a cycle of functional decline.

The mechanism is simple: reduced appetite, decreased motivation to prepare or consume meals, and altered taste perception. The PHQ-9 and GAD-7 are validated, rapid screening tools that take under 3 minutes to administer. The American Psychiatric Association recommends screening for depression in any patient with unexplained weight loss lasting more than 4 weeks [11].

Eating disorders extend beyond anorexia nervosa. Avoidant/restrictive food intake disorder (ARFID) is increasingly recognized in adults, particularly those with sensory processing differences or a history of GI illness. Unlike anorexia nervosa, ARFID does not involve body image distortion. The DSM-5-TR criteria require persistent failure to meet nutritional needs leading to significant weight loss, nutritional deficiency, or dependence on supplements [11].

Substance use disorders (alcohol, stimulants, opioids) frequently cause weight loss through appetite suppression, malabsorption, or neglect of nutrition. A careful social history and urine drug screen should be part of the standard workup.

Social isolation in older adults deserves its own mention. A 2020 study in JAMA Internal Medicine (N=5,888 Medicare beneficiaries) found that food-insecure older adults had 2.3 times the odds of unintentional weight loss compared to food-secure counterparts [12]. Simply asking "Do you have trouble getting enough food?" is a screening question that many clinicians skip.

Infectious and Inflammatory Diseases

Chronic infections remain a significant cause of weight loss, particularly in immunocompromised patients or those with travel exposure. Tuberculosis, HIV, endocarditis, and chronic hepatitis C are the infections most frequently associated with unintentional weight loss in developed countries [4].

HIV-associated wasting syndrome, defined as involuntary loss of more than 10% of baseline body weight plus chronic diarrhea or fever lasting more than 30 days, was once a defining AIDS illness. With modern antiretroviral therapy, it is less common but still occurs in patients with undiagnosed HIV or those not engaged in care. The CDC recommends HIV screening for all patients aged 13 to 64, and an HIV test should be included in the weight-loss workup if not recently done [13].

Tuberculosis classically presents with weight loss, night sweats, and chronic cough. Interferon-gamma release assays (IGRA) or tuberculin skin testing remain the standard screening approach. TB should be considered particularly in patients born in endemic regions, those with a history of incarceration, or immunocompromised individuals.

Autoimmune and systemic inflammatory diseases (rheumatoid arthritis, systemic lupus erythematosus, giant cell arteritis, and vasculitis) can cause weight loss through chronic inflammation and elevated cytokine levels. An elevated ESR or CRP with weight loss in a patient over 50 should prompt consideration of giant cell arteritis, which has a prevalence of approximately 20 per 100,000 in adults over 50 in Northern European populations [14].

Medications That Cause Weight Loss

A thorough medication review is one of the highest-yield steps in the weight-loss workup. Dozens of commonly prescribed drugs cause weight loss as a side effect, and patients frequently do not connect the two.

The most common culprits include metformin (through GI side effects and reduced appetite), topiramate (which suppresses appetite centrally), GLP-1 receptor agonists such as semaglutide and tirzepatide (which produce dose-dependent weight reduction of 10% to 22.5% depending on agent and dose) [15], SSRIs (particularly fluoxetine in the first 6 months), stimulant medications for ADHD, and acetylcholinesterase inhibitors used in dementia.

Polypharmacy in older adults compounds the problem. A patient on metformin, an SSRI, and a cholinesterase inhibitor may experience additive appetite suppression from three different mechanisms. The Beers Criteria, updated by the American Geriatrics Society in 2023, flag several medications with weight-loss potential that deserve reassessment in older adults [16].

Drug-induced dysgeusia (altered taste) is an underrecognized contributor. ACE inhibitors, metronidazole, and lithium are among the medications that alter taste perception, reducing food enjoyment and intake. Asking "Has food started tasting different?" can uncover this mechanism.

The Diagnostic Workup: A Structured Approach

The AGA's 2017 technical review on the evaluation of unintentional weight loss recommends a staged approach [1]. The initial evaluation includes a comprehensive history (dietary changes, medication review, psychiatric screening, social history), physical examination, and baseline laboratory testing.

First-line labs should include a complete blood count, comprehensive metabolic panel, thyroid-stimulating hormone, C-reactive protein, erythrocyte sedimentation rate, lactate dehydrogenase, fasting glucose, HbA1c, HIV test, urinalysis, and hepatitis C antibody. This panel catches the majority of common metabolic, infectious, and hematologic causes.

Dr. Michael Djordjevic, an internist at the Cleveland Clinic, has noted: "The biggest mistake in the weight-loss workup is skipping the basics. A CBC, CMP, and TSH will point you in the right direction in 60% of cases before you order a single scan" [5].

If first-line testing is unrevealing, second-tier testing based on clinical suspicion includes CT of the chest, abdomen, and pelvis (the single most useful imaging study for occult malignancy), upper endoscopy, celiac serology (tTG-IgA), fecal elastase-1, and age-appropriate cancer screening if not current.

A 2021 cohort study in The Lancet (N=63,973 primary-care patients with coded unintentional weight loss) found that 5.8% were diagnosed with cancer within 6 months, with the highest yield from CT imaging of the abdomen [17]. The study's data informed the UK's NICE guideline update recommending urgent cancer-pathway referral for unexplained weight loss in patients over 60.

In 16% to 28% of cases, no diagnosis is reached after initial workup [1]. These patients require follow-up at 3- and 6-month intervals with repeat weights, because many diagnoses declare themselves over time. A prospective study following patients with initially unexplained weight loss found that 75% of those who were eventually diagnosed received their diagnosis within 12 months of presentation [3].

When to Seek Medical Evaluation

Any adult who has lost 5% or more of body weight over 6 months without trying should see a clinician. The threshold drops to any noticeable unintentional weight loss in adults over 65, where even 3% to 5% loss correlates with increased mortality and functional decline.

Certain red flags warrant urgent evaluation: weight loss combined with night sweats, a new palpable mass or lymphadenopathy, persistent fever, dysphagia, hemoptysis, or rectal bleeding. These combinations significantly increase the pre-test probability of malignancy and should trigger expedited workup within 2 weeks per NICE urgent-referral guidelines [17].

A baseline screening lab panel for any patient presenting with 5% unintentional weight loss over 6 months should include CBC, CMP, TSH, HbA1c, CRP, HIV, hepatitis C antibody, urinalysis, and LDH, with a CT abdomen/pelvis considered early in patients over 60 or those with alarm symptoms.